ReidJRobisonMDMBA
Psychiatry • Orem, UTChild & Adolescent Psychiatry, Psychopharmacology, Integrative Psychiatry
Psychiatrist at DoctorReid.com, a public benefit organization). Principal Investigator at Cedar Clinical Research. Medical Director at Center for Change. Co-founded Cedar Psychiatry, acquired by Numinus. Co-founded Tute Genomics and Anolinx, both acquired. Adjunct Faculty at University of Utah and BYU. Founded Polizzi Free Clinic and Psychedelic Institute.
Dr. Robison is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1788 N State St
Orem, UT 84057Phone+1 801-839-5227
Summary
- Dr. Reid Robison is a psychiatrist in Orem, UT, Principal Investigator at Numinus, and Medical Director at Center for Change. He received his medical degree from University of Utah School of Medicine. He specializes in psychopharmacology, treatment-resistant conditions, eating disorders & psychedelic medicine. He has dozens publications, hundreds of citations, and has led over 250 clinical trials.
Education & Training
Unviersity of Utah Department of Biomedical InformaticsPost doc, Bioinformatics, NLM Fellow, 2009 - 2010- University of Utah CTSAFellowship, 2008 - 2009
University of Utah HealthResidency, Psychiatry, 2005 - 2009- University of Utah HealthInternship, Psychiatry, 2005 - 2006
- University of Utah Eccles School of BusinessMBA, Business, 2002 - 2005
University of Utah School of MedicineClass of 2005
Certifications & Licensure
UT State Medical License 2006 - 2026
AZ State Medical License 2023 - 2025
CO State Medical License 2023 - 2025
NV State Medical License 2023 - 2025
WI State Medical License 2023 - 2025
WY State Medical License 2023 - 2025
ID State Medical License 2007 - 2024- American Board of Psychiatry and Neurology Psychiatry
- Join now to see all
Awards, Honors, & Recognition
- Fellow American Psychiatric Association, 2024
Clinical Trials
- Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults Start of enrollment: 2023 Jan 31
- Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Start of enrollment: 2023 Jan 19
- Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) Start of enrollment: 2022 May 06
- Join now to see all
Publications & Presentations
PubMed
- 12 citationsCase report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa.Johanna Louise Keeler, Janet Treasure, Hubertus Himmerich, Madeline Brendle, Claire Moore
Frontiers in Psychiatry. 2023-01-01 - 15 citationsA case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders.Reid Robison, Adele Lafrance, Madeline Brendle, Michelle Smith, Claire Moore
Journal of Eating Disorders. 2022-05-06 - 12 citationsThe Effect of Personality Disorder Symptoms on Response to Treatment With Methylphenidate Transdermal System in Adults With Attention-Deficit/Hyperactivity DisorderJohn L. Olsen, Frederick W. Reimherr, Barrie K. Marchant, Paul H. Wender, Reid J. Robison
The Primary Care Companion for CNS Disorders. 2012-10-11
Press Mentions
Mind Medicine MindMed : Q2 2024 Earnings Call PresentationAugust 14th, 2024- Mind Medicine MindMed : Investor Presentation - Q2 2024 Earnings Call PresentationAugust 13th, 2024
- MindMed Gets Breakthrough Designation for LSD Candidate in AnxietyMarch 15th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
